hGH fragment comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-04-09. Numbers and descriptions here follow the published literature rather than marketing material.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
=== DNA and RNA synthesis === ATP is one of four monomers required in the synthesis of RNA. The process is promoted by RNA polymerases. A similar process occurs in the formation of DNA, except that ATP is first converted to the deoxyribonucleotide dATP. Like many condensation reactions in nature, DNA replication and DNA transcription also consume ATP.
All of these chemical identifiers, combined with distinct morphological features characteristic of tracheids allowed for the assignment of Protopodocarpoxylon to the sample. The presence of multiple biomarkers, each of which correspond to different groups of organisms allows potential identities to be narrowed down. When combined with phenotypic characteristics, specific biomarkers like sugiol become very strong tools in identifying unknown organisms.
Thymulin (also known as thymic factor or its old name facteur thymique serique) is a nonapeptide produced by two distinct epithelial populations in the thymus first described by Bach in 1977. It requires zinc for biological activity. Its peptide sequence is H-Pyr-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn-OH. The hormone is believed to be involved in T-cell differentiation and enhancement of T and NK cell actions. Besides this rather paracrine or auto-organic effects on the thymus dependent immune system, thymulin seems to have neuroendocrine effects as well. There exist bidirectional interactions between thymic epithelium and the hypothalamus-pituitary axis (for example, thymulin follows a circadian rhythm and physiologically elevated ACTH levels correlate positively with thymulin plasma levels and vice versa). A recent focus has been on the role of thymulin as an effector on proinflammatory mediators/cytokines. A peptide analog of thymulin (PAT) has been found to have analgesic effects in higher concentrations and particularly neuroprotective anti-inflammatory effects in the CNS. Astrocytes seem to be the target for thymulin for this effect. Researchers hope to develop drugs thwarting inflammatory processes associated with neurodegenerative diseases and even rheumatism with the help of thymulin analogs. Significantly decreased thymulin levels have been associated with anorexia nervosa.
The birth of most Mexican drug cartels is traced to former Mexican Judicial Federal Police agent Miguel Ángel Félix Gallardo (Spanish: El Padrino, lit. 'The Godfather'), who founded the Guadalajara Cartel in 1980 and controlled most of the illegal drug trade in Mexico and the trafficking corridors across the Mexico–U.S. border along with Juan García Ábrego throughout the 1980s. He started by smuggling marijuana and opium into the U.S., and was the first Mexican drug chief to link up with Colombia's cocaine cartels in the 1980s. Through his connections, Félix Gallardo became the person at the forefront of the Medellín Cartel, which was run by Pablo Escobar. This was accomplished because Félix Gallardo had already established a marijuana trafficking infrastructure that stood ready to serve the Colombia-based cocaine traffickers. There were no other cartels at that time in Mexico. He oversaw operations with his cronies and the politicians who sold him protection. The Guadalajara Cartel suffered a major blow in 1985 when the group's co-founder Rafael Caro Quintero was captured, and later convicted, for the murder of DEA agent Enrique "Kiki" Camarena. Félix Gallardo then kept a low profile and in 1987 he moved with his family to Guadalajara. According to Peter Dale Scott, the Guadalajara Cartel prospered largely because it enjoyed the protection of the Dirección Federal de Seguridad (DFS), under its chief Miguel Nazar Haro. Félix Gallardo was arrested on April 8, 1989.
It is not possible to determine the structure of a protein with H/D exchange other than neutron crystallography nor is it possible to define secondary structural elements. The reasons for this are related to the way in which protein structure slows exchange. Exchange rates are a function of two parameters: solvent accessibility and hydrogen bonding. Thus an amide which is part of an intramolecular hydrogen bond will exchange slowly if at all, while an amide on the surface of protein hydrogen bonded to water will exchange rapidly. Amides buried from the solvent but not hydrogen bonded may also have very slow exchange rates. Because both solvent accessibility and hydrogen bonding contribute to the rate of exchange, it becomes difficult to attribute a given exchange rate to a structural element without crystallography or NMR structural data. H–D exchange has been used to characterize the folding pathway of proteins, by refolding the protein under exchange conditions. In a forward exchange experiment (H to D), a pulse of deuterium is added after various amounts of refolding time. The parts of the structure that form rapidly will be protected and thus not exchanged, whereas areas that fold late in the pathway will be exposed to the exchange for longer periods of time. Thus H/D exchange can be used to determine the sequence of various folding events. Factors determining the time resolution of this approach are the efficiency of mixing and how quickly the quench can be performed after the labeling.
Sources: en.wikipedia.org
== Research directions == Outside of H. pylori eradication and ulcer management, the broader antimicrobial potential and gastric‑protective roles of bismuth subcitrate are not well studied in clinical trials; this is a potential research direction. Bismuth is also studied on potential antiviral and antileishmanial applications.
== Labour market and employment == The Danish labour market is characterized by a high degree of union membership rates and collective agreement coverage dating back from Septemberforliget (The September Settlement) in 1899 when the Danish Confederation of Trade Unions and the Confederation of Danish Employers recognized each other's right to organise and negotiate. The labour market is also traditionally characterized by a high degree of flexicurity, i.e. a combination of labour market flexibility and economic security for workers. The degree of flexibility is in part maintained through active labour market policies. Denmark first introduced active labour market policies (ALMPs) in the 1990s after an economic recession that resulted in high unemployment rates. Its labour market policies are decided through tripartite cooperation between employers, employees and the government. Denmark has one of the highest expenditures on ALMPs and in 2005, spent about 1.7% of its GDP on labour market policies. This was the highest amongst the OECD countries. Similarly, in 2010 Denmark was ranked number one amongst Nordic countries for expenditure on ALMPs. Denmark's active labour market policies particularly focus on tackling youth unemployment. They have had a "youth initiative" or the Danish Youth Unemployment Programme in place since 1996. This includes mandatory activation for those unemployed under the age of 30. While unemployment benefits are provided, the policies are designed to motivate job-seeking. For example, unemployment benefits decrease by 50% after 6 months.
==== Silver mirror reaction ==== The silver mirror reaction involves the conversion of silver nitrate to Ag(NH3)OH. Ag(NH3)OH is subsequently reduced into colloidal silver using an aldehyde containing molecule such as a sugar. The silver mirror reaction is as follows:
Although American rocket pioneer Robert H. Goddard developed, patented, and flew small liquid-propellant rockets as early as 1914, the United States was the only one of the three major allied World War II powers to not have its own rocket program, until Von Braun and his engineers were expatriated from Nazi Germany in 1945. The US acquired a large number of V-2 rockets and recruited von Braun and most of his engineering team in Operation Paperclip. The team was sent to the Army's White Sands Proving Ground in New Mexico, in 1945. They set about assembling the captured V-2s and began a program of launching them and instructing American engineers in their operation. These tests led to the first photos of Earth from space, and the first two-stage rocket, the WAC Corporal-V-2 combination, in 1949. The German rocket team was moved from Fort Bliss to the Army's new Redstone Arsenal, located in Huntsville, Alabama, in 1950. From here, von Braun and his team developed the Army's first operational medium-range ballistic missile, the Redstone rocket, derivatives of which launched both America's first satellite, and the first piloted Mercury space missions. It became the basis for both the Jupiter and Saturn family of rockets.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.